Table 1 Patient population participating in this study.
Experiment | Group | N; (Male/Female) | Age (years ± SD) | Phenotype (% IBD;% lung fibrosis) |
|---|---|---|---|---|
CyTOF | HPS-1 | 8 (4/4) | 44 ± 12 | 25% PF |
Controls | 12 (5/7) | 47 ± 14 | ||
Serum proteomics | HPS-1 | 11 (3/8) | 39 ± 14 | 18% PF; 36% IBD |
Controls | 50 (26/24) | 35 ± 9 | ||
Transcriptomics | HPS-1 | 4 (2/2) | 36 ± 8 | 25% PF |
Controls | 4 (2/2) | 26 ± 1 | ||
Functional experiments | HPS-1 | 10 (7/3) | 41 ± 11 | 10% PF |
Controls | 12 (8/4) | 37 ± 12 | ||
Spatial transcriptomics | HPS-1 | 1 (0/1) | 8 | IBD |
